Dumont & Blake Investment Advisors LLC Trims Stake in Stryker Co. (SYK)

Dumont & Blake Investment Advisors LLC reduced its position in shares of Stryker Co. (NYSE:SYK) by 32.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,671 shares of the medical technology company’s stock after selling 2,675 shares during the period. Dumont & Blake Investment Advisors LLC’s holdings in Stryker were worth $1,008,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the company. Atlantic Trust LLC acquired a new position in shares of Stryker in the second quarter worth approximately $105,000. Centaurus Financial Inc. acquired a new position in shares of Stryker in the second quarter worth approximately $110,000. Kaizen Advisory LLC lifted its stake in shares of Stryker by 142.6% in the second quarter. Kaizen Advisory LLC now owns 752 shares of the medical technology company’s stock worth $127,000 after acquiring an additional 442 shares during the period. CX Institutional acquired a new position in shares of Stryker in the second quarter worth approximately $133,000. Finally, NumerixS Investment Technologies Inc acquired a new position in shares of Stryker in the second quarter worth approximately $135,000. Institutional investors own 75.19% of the company’s stock.

SYK traded down $4.16 during trading on Friday, hitting $168.94. The company’s stock had a trading volume of 1,689,300 shares, compared to its average volume of 1,306,268. Stryker Co. has a twelve month low of $146.80 and a twelve month high of $179.84. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.15 and a current ratio of 1.83. The firm has a market cap of $65.91 billion, a PE ratio of 26.67, a price-to-earnings-growth ratio of 2.47 and a beta of 0.59.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Tuesday, July 24th. The medical technology company reported $1.76 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.73 by $0.03. Stryker had a return on equity of 26.93% and a net margin of 8.28%. The firm had revenue of $3.32 billion for the quarter, compared to analyst estimates of $3.31 billion. During the same period in the previous year, the firm earned $1.53 earnings per share. The company’s revenue was up 10.3% compared to the same quarter last year. Research analysts predict that Stryker Co. will post 7.25 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 31st. Shareholders of record on Friday, September 28th will be paid a $0.47 dividend. This represents a $1.88 annualized dividend and a yield of 1.11%. The ex-dividend date of this dividend is Thursday, September 27th. Stryker’s dividend payout ratio (DPR) is presently 28.97%.

In other news, VP Katherine Ann Owen sold 37,866 shares of the company’s stock in a transaction that occurred on Wednesday, September 5th. The stock was sold at an average price of $166.84, for a total transaction of $6,317,563.44. Following the transaction, the vice president now directly owns 11,367 shares of the company’s stock, valued at $1,896,470.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Glenn S. Boehnlein sold 750 shares of the company’s stock in a transaction that occurred on Monday, October 1st. The stock was sold at an average price of $178.17, for a total value of $133,627.50. Following the transaction, the chief financial officer now directly owns 2,785 shares in the company, valued at $496,203.45. The disclosure for this sale can be found here. 7.40% of the stock is currently owned by insiders.

A number of equities analysts recently commented on the company. Barclays assumed coverage on Stryker in a research note on Monday. They issued an “overweight” rating and a $198.00 price objective on the stock. JPMorgan Chase & Co. lifted their price objective on Stryker to $200.00 and gave the stock an “overweight” rating in a research note on Thursday, September 13th. BTIG Research reaffirmed a “buy” rating and issued a $187.00 price objective on shares of Stryker in a research note on Wednesday, September 12th. Needham & Company LLC reaffirmed a “hold” rating on shares of Stryker in a research note on Tuesday, September 11th. Finally, Zacks Investment Research lowered Stryker from a “buy” rating to a “hold” rating in a research note on Wednesday, August 8th. Eight equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $180.71.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.

Featured Story: Float

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply